• Cortica

  Participated · Series D · Oct 2023

  Cortica delivers whole-child, value-based autism care through an integrated clinical model that spans medical treatment, neurodiversity-affirming behavioral therapy, developmental therapies (speech, occupational, physical, and music), and family support. The company addresses conditions that frequently co-occur with autism, including sleep disorders, seizures, psychiatric comorbidities, gastrointestinal, communication, behavioral, and sensorimotor issues. Cortica employs more than 1,800 experts across disciplines, including pediatric neurologists, developmental pediatricians, epileptologists, nurse practitioners, speech-language pathologists, occupational and physical therapists, music therapists, BCBA clinicians, and marriage and family therapists. Researchers and physicians in its Cortica innovation network conduct outcomes research, lead clinical trial recruitment, and have assembled a large longitudinal and cross-sectional dataset in autism and neurodevelopment. The company intends to use new funding to continue national scaling of whole-child autism value-based care and to invest in technology, data capture, clinical decision support, research, and optimization of the clinician and patient experience. Cortica is led by CEO and MD Neil Hattangadi and was founded to address the fragmented care journey families experience when seeking autism diagnoses and treatment. Cortica, founded in 2017 and based in San Diego, CA, is a physician-led autism services provider that blends pediatric neurology, developmental pediatrics, research-based therapies, and technology into integrated care programs. The company operates a network of clinicians including pediatric neurologists, developmental pediatricians, nurse practitioners, therapists, and behavior analysts. Cortica has built the Cortica Innovation Network to conduct outcomes research and support clinical trial recruitment. Through organic growth and acquisitions it now owns and operates 23 integrated autism centers and will serve more than 10,000 neurodivergent children and families this year. The organization employs more than 1,600 staff across clinical and support roles. Leadership is headed by CEO Neil Hattangadi. Cortica delivers a “whole-child” medical and behavioral care model for autism and other neurodiverse conditions, integrating medical advances with behavioral analysis, developmental therapies, and family support. Its care platform is enabled by Axon, a technology infrastructure for care coordination and data capture. The company operates centers across five states—California, Illinois, New Jersey, New York and Texas—each led by neurologists and other physicians. Cortica is running multiple clinical trials, including several funded by the National Institutes of Health, across neuroimaging, neuromodulation, molecular diagnostics, biotech therapeutics, and digital therapeutics. The company plans to use new investment to bring its care model to more families across the country. Leadership is headed by co-founder and CEO Neil Hattangadi, M.D. Cortica is a tech-enabled clinical services provider delivering coordinated care for autism and other neurodevelopmental conditions. Its treatment model assembles multidisciplinary teams to foster holistic child development and empower families. The model combines an “inside out” focus on medical diagnosis, nutrition, supplements, neurofeedback and other health interventions with an “outside-in” focus on environmental and learning optimizations such as speech and language therapy, neurological music therapy, occupational therapy, progressive ABA, and parent education. Cortica conducts sponsored and NIH-funded research and is considered a leader in autism outcomes research, having run multiple clinical studies demonstrating therapeutic benefits and cost-effectiveness of its platform. The company is accelerating growth by expanding centers across multiple states. Cortica is led by co-founders Neil Hattangadi, M.D. (CEO) and Suzanne Goh, M.D., BCBA (Chief Medical Officer), who met at Harvard Medical School.

No current team members are available.